Titles
- Medicare Part B drug payments: impact of price substitutions based on 2018 average sales prices1
- Medicare Part D beneficiaries at serious risk of opioid misuse or overdose: a closer look1
- Medicare and Medicaid: alignment of managed care plans for dual-eligible beneficiaries : report to Congressional committees1
- Medicare laboratory test expenditures increased in 2018, despite new rate reductions1
- Montana Medicaid Fraud Control Unit: 2019 onsite inspection1
- NIH has acted to protect confidential information handled by peer reviewers, but it could do more1
- National Background Check Program for long-term-care providers: assessment of state programs concluded in 20191
- National biodefense strategy: additional efforts would enhance likelihood of effective implementation : report to Congressional committees1
- Onsite surveys of nursing homes during the COVID-19 pandemic: March 23–May 30, 20201
- Opioid use disorder: treatment with injectable and implantable buprenorphine : report to Congressional committees1
- Opioid use in Medicare Part D continued to decline in 2019, but vigilance is needed as COVID-19 raises new concerns1
- Opioids in Medicaid: concerns about opioid use among beneficiaries in six Appalachian states in 20181
- Organ transplants: changes in allocation policies for donated livers and lungs : report to Congressional requesters1
- Part D plans generally include drugs commonly used by dual eligibles: 20201
- Prescription drug monitoring programs: views on usefulness and challenges of programs : report to Congressional committees1
- Prescription drugs: Department of Veterans Affairs paid about half as much as Medicare Part D for selected drugs in 2017 : report to the Ranking Member, Committee on the Budget, U.S. Senate1
- Science and tech spotlight: CRISPR gene editing1
- Selected health care coalitions increased involvement in whole community preparedness but face developmental challenges following new requirements in 20171
- Social Security disability: action needed to help agency staff understand and follow policies related to prescription opioid misuse : report to the Subcommittee on Social Security, Committee on Ways and Means, House of Representatives1
- Some manufacturers reported inaccurate drug product data to CMS1